Acceleron Clinical Trials

Clinical Trials

Clinical Trials

At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders and neuromuscular diseases.

  • We are developing luspatercept, our lead product candidate, for the treatment of the chronic anemias in myelodysplastic syndromes (MEDALIST Phase 3 study), and beta-thalassemia (BELIEVE Phase 3 study) under a global partnership with Celgene. The goal of these studies is to reduce or eliminate the need for regular red blood cell transfusions.
  • ACE-083 is being studied in a two-part Phase 2 study in facioscapulohumeral muscular dystrophy (FSHD), with the goal of improving muscle strength and function in target muscles.

With multiple Phase 2 and Phase 3 trials ongoing and new INDs expected in 2017 and 2018, we believe that we are poised to make a meaningful difference in the lives of patients with severe and rare diseases who have few or no therapeutic options.

The clinical trials listed below are Acceleron or partner-sponsored trials that are actively recruiting patients. Each trial in the list contains a link to clinicaltrials.gov, where you will find a full description and contact information.


Drug Study Phase Disease Study ID
Luspatercept MEDALIST
Phase III
Lower-Risk
Myelodysplastic Syndromes (MDS)
NCT02631070
Luspatercept BELIEVE
Phase III
Beta-Thalassemia NCT02604433
Luspatercept Phase II Extension MDS NCT02268383
Luspatercept Phase II Extension Beta-Thalassemia NCT02268409
Luspatercept Phase II Beta-Thalassemia NCT01749540
Luspatercept Phase II Anemia in Lower-Risk MDS NCT01749514
Sotatercept Phase II Myelofibrosis NCT01712308
ACE-083 Phase II Facioscapulohumeral Muscular Dystrophy NCT02927080
Acceleron trials listed as recruiting or active on www.clinicaltrials.gov